Results 41 to 50 of about 1,959,681 (261)

Treatment of newly diagnosed severe aplastic anemia in children: Evidence‐based recommendations

Pediatric Blood &Cancer, Volume 71, Issue 8, August 2024.
Abstract Severe aplastic anemia (SAA) is a rare potentially fatal hematologic disorder. Although overall outcomes with treatment are excellent, there are variations in management approach, including differences in treatment between adult and pediatric patients. Certain aspects of treatment are under active investigation in clinical trials.
Kristin A. Shimano, Jennifer A. Rothman, Steven W. Allen, Paul Castillo, Jill L. O. de Jong, Yigal Dror, Amy E. Geddis, Bonnie W. Lau, Catherine McGuinn, Anupama Narla, Kathleen Overholt, Maria A. Pereda, Anjali Sharathkumar, Ghadir Sasa, Taizo A. Nakano, Kasiani Myers, Nicholas J. Gloude, Larisa Broglie, Jessica Boklan   +18 more
wiley   +1 more source

Improvements in the preparation of heterologous antilymphocyte globulin with special reference to absorption and diethylaminoethyl cellulose batch production [PDF]

, 1969
Antilymphocyte gamma-G globulin (ALGG) was produced from the serum of immunized horses. Modifications of the preliminary absorption techniques permitted the removal of undesirable, extraneous antibodies.
Amend, JR, Blanchard, H, Gecelter, L, Groth, CG, Kashiwagi, N, Starzl, TE   +5 more
core  

A heart transplant center experience with basiliximab induction strategies: A double edged sword?

Clinical Transplantation, Volume 38, Issue 4, April 2024.
Abstract Background The use of induction immunosuppression for heart transplantation (HT) is debated given the uncertain benefit and potential risks of infection and malignancy. Methods This is a retrospective single‐center analysis of 475 consecutive HT recipients from 2003 to 2020 grouped by use of induction with basiliximab group (BG) and the no ...
Luise Holzhauser, Maxwell Norris, Maria Molina, Susan Chambers, Swethika Sundaravel, Eman Rashed, Ketan Gala, Tara Fallah, Therese Bittermann, Nosheen Reza, Teresa Wang, Pavan Atluri, Lee Goldberg, Rhondalyn McLean, Eliot Peyster   +14 more
wiley   +1 more source

Advances in the Use of Biologics and Biomaterials toward the Improvement of Pancreatic Islet Graft Survival in Type 1 Diabetes

Advanced NanoBiomed Research, Volume 4, Issue 3, March 2024.
Although islet transplantation has the potential to serve as a curative treatment for type 1 diabetes, there are many hurdles to achieving long‐term islet graft survival. This review discusses the recent advances in strategies to improve islet survival function using exogenous compounds and conformal coatings as a promising tool for improving islet ...
Michael Yilma Yitayew, Marina Luginina, Maryam Tabrizian   +2 more
wiley   +1 more source

Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japanese Society for Transplantation and Cellular Therapy

American Journal of Hematology, Volume 99, Issue 2, Page 263-273, February 2024.
Abstract We retrospectively evaluated the effect of 17 individual comorbidities, defined by the hematopoietic cell transplantation (HCT)‐specific comorbidity index, on non‐relapse mortality (NRM) and overall survival (OS) in 9531 patients aged between 16 and 70 years who underwent their first allogeneic HCT from 8/8 and 7/8 allele‐matched unrelated ...
Takaaki Konuma, Kaito Harada, Akihito Shinohara, Naoyuki Uchida, Naoki Shingai, Ayumu Ito, Yukiyasu Ozawa, Masatsugu Tanaka, Masashi Sawa, Makoto Onizuka, Yuta Katayama, Nobuhiro Hiramoto, Nobuaki Nakano, Takafumi Kimura, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Hideki Nakasone, Junya Kanda   +18 more
wiley   +1 more source

Malignant lymphomas in transplantation patients: a review of the world experience. [PDF]

, 1970
Malignant lymphomas developed in 9 renal homograft recipients treated at widely separated transplantation centers. The development of these tumors appears to be an indirect complication of organ transplantation and/or the measures taken to prevent ...
Penn, I, Starzl, TE
core  

Single‐Center Outcomes of Epstein–Barr Virus DNAemia in Adult Solid Organ Transplant Recipients

Journal of Transplantation, Volume 2024, Issue 1, 2024.
Background. Immunosuppression in solid organ transplantation (SOT) increases the risk of Epstein–Barr virus (EBV) DNAemia, which may herald development of posttransplant lymphoproliferative disease (PTLD). Few studies have characterized the incidence, risk factors, and clinical impact of EBV DNAemia in adult SOT recipients (SOTR). Methods.
Sara W. Dong, Barbra M. Blair, Carolyn D. Alonso, Massimiliano Veroux   +3 more
wiley   +1 more source

Stress Effect of Antilymphocyte Serum [PDF]

BMJ, 1969
Antilymphocyte serum prepared in the rabbit against guinea-pig lymph node cells produces a sustained weight loss when injected into normal guinea-pigs over 14 days, compared with a very transient loss produced by normal rabbit serum. Antilymphocyte serum also produces a much greater increase in plasma cortisol level than normal rabbit serum.
E J, Field, D B, Cook
openaire   +2 more sources

Fulminant Myocarditis with SARS‐CoV‐2 Infection: A Narrative Review from the Case Studies

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2024, Issue 1, 2024.
One of the severe complications of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection is myocarditis. However, the characteristics of fulminant myocarditis with SARS‐CoV‐2 infection are still unclear. We systematically reviewed the previously reported cases of fulminant myocarditis associated with SARS‐CoV‐2 infection from ...
Ryohei Ono, Togo Iwahana, Kaoruko Aoki, Hirotoshi Kato, Sho Okada, Yoshio Kobayashi, Jianhai Yin   +6 more
wiley   +1 more source

Cytokine Release Syndrome After CAR T‐Cell Therapy in a 35‐Year‐Old Patient With Pneumocystis jiroveci Pneumonia and Cytomegalovirus Viremia

Case Reports in Medicine, Volume 2024, Issue 1, 2024.
Background: The risk of cytokine release syndrome (CRS) in patients with infections prior to chimeric antigen receptor T‐cell (CAR T‐cell) therapy represents an important and underreported event. Patients with active infections needing prompt CAR T‐cell therapy to treat aggressive hematologic malignancies remain a clinical challenge.
Kristina A. Helms, Massimo Conese
wiley   +1 more source